Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
225 participants
INTERVENTIONAL
2021-07-09
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
90 subjects, from 18-85 years of age, undergoing cardiac surgery with median sternal incision will be enrolled at Mount Sinai Morningside Hospital Center. Study participation will last from the time of pre-operative evaluation to 72 hours after surgery. Subjects will be randomly assigned to receive 1 of the 3 different regimens at the beginning of surgery. Opioid consumption and pain scores after surgery will be evaluated. Though unlikely, risks include systemic absorption of local anesthetic, which can result in both central nervous system and cardiac toxicity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Erector Spinae Block and Pecto-Intercostal Facial Block For Enhanced Recovery in Adult Cardiac Surgery
NCT05475561
Comparison of Erector Spinae Plane Block and Pectoral Nerve Block for Acute and Chronic Pain in Mastectomies
NCT05069805
Different Volumes of Erector Spinae Plane Block for Breast Surgery
NCT05232084
Erector Spinae Plane Block in Post-operative Recovery in Cardiac Surgery With Median Sternotomy.
NCT05356715
ESP Versus PIFB for Analgesia in Open Cardiac Surgery: a Randomized Control Trial
NCT06322810
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESP group
Patient will receive ESP block with ultrasound guidance the transverse process of the vertebra at T7 is visualized and 20 mL of 0.25% bupivacaine will be injected between the transverse process and the erector spinae muscle on each side using a 21-gauge block needle.
ESP block
peripheral nerve block
Ultrasound
Ultrasound guidance
Bupivacain
10-20 mL of 0.25% bupivacaine
PIF group
Patient will receive PIF block after intubation with ultrasound placed 1-2 cm lateral to the sternal border and the pectoralis major and external intercostal muscles are visualized at the level of ribs 3-4 where 10 mL of 0.25% bupivacaine will be injected on each side using a 21-gauge block needle.
PIF block
peripheral nerve block
Ultrasound
Ultrasound guidance
Bupivacain
10-20 mL of 0.25% bupivacaine
No Block group
Patient will not receive block.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESP block
peripheral nerve block
PIF block
peripheral nerve block
Ultrasound
Ultrasound guidance
Bupivacain
10-20 mL of 0.25% bupivacaine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Scheduled to undergo cardiac procedures involving sternotomy
* All genders
Exclusion Criteria
* Urgent or emergent surgery
* Contraindications to administration of local anesthesia (e.g. local anesthetic allergy)
* History of substance abuse or chronic opioid use
* Patient refusal or inability to consent
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Icahn School of Medicine at Mount Sinai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ali Nima Shariat
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali Shariat, M.D.
Role: PRINCIPAL_INVESTIGATOR
Mount Sinai West and Morningside Hospitals
Himani Bhatt, D.O.
Role: STUDY_DIRECTOR
Mount Sinai West and Morningside Hospitals
Shenghao Fang, M.D.
Role: STUDY_DIRECTOR
Mount Sinai West and Morningside Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai Morningside Hospital
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY-20-01473
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.